Lee Michael S, Jimenez Andrew E, Owens Jade S, Curley Andrew J, Paraschos Olivia A, Maldonado David R, Lall Ajay C, Domb Benjamin G
American Hip Institute Research Foundation, Chicago, Illinois, USA.
American Hip Institute, Chicago, Illinois, USA.
Orthop J Sports Med. 2022 Jun 8;10(6):23259671221097372. doi: 10.1177/23259671221097372. eCollection 2022 Jun.
Cigarette smoking has been shown to negatively affect outcomes after hip arthroscopy for femoroacetabular impingement syndrome (FAIS). The effect of cessation of cigarette smoking before surgery has not been well established.
(1) To report minimum 2-year patient-reported outcomes (PROs) of former smokers who underwent primary hip arthroscopy for FAIS and (2) to compare these results with those of a propensity-matched control group of nonsmokers.
Cohort study; Level of evidence, 3.
Data were collected for all patients who underwent primary hip arthroscopy for FAIS between December 2008 and November 2017. Patients were eligible if they indicated that they had previously smoked cigarettes but had quit smoking at least 1 month before surgery and had minimum 2-year postoperative outcomes for the modified Harris Hip Score (mHHS), Nonarthritic Hip Score (NAHS), and visual analog scale (VAS) for pain. The percentage of hips achieving the minimal clinically important difference (MCID) were recorded. The study group was then propensity matched in a 1:1 ratio by age, sex, and body mass index (BMI) to patients who had never smoked.
A total of 83 former-smoking patients (84 hips; age, 45.0 ± 13.5 years) were included at a median follow-up of 38.6 months (interquartile range, 27.5-48.2 months); all patients had stopped smoking at a mean ± standard deviation of 14.3 ± 24.5 months preoperatively. Former smokers demonstrated significant improvement from preoperatively to the minimum 2-year follow-up for all recorded PROs ( < .001 for all) and achieved the MCID for the mHHS, NAHS, and VAS at favorable rates (75.0%-81.6%). Logistic regression analysis did not identify a significant relationship between cessation time and rates of achieving MCID for mHHS, NAHS, or VAS. When compared with 84 never-smokers (84 hips), the former smokers demonstrated similar preoperative scores, postoperative scores, and improvement on all recorded PROs ( > .05 for all). Both groups achieved MCID for mHHS, NAHS, and VAS at similar rates and demonstrated similar rates of revision surgery.
Former smokers who underwent primary hip arthroscopy for FAIS demonstrated significant improvement in PROs at minimum 2-year follow-up. When compared with a propensity-matched control group of never-smokers, they achieved similar postoperative PROs and rates of achieving psychometric thresholds.
已有研究表明,吸烟会对髋关节镜治疗股骨髋臼撞击综合征(FAIS)后的疗效产生负面影响。术前戒烟的效果尚未明确。
(1)报告接受初次髋关节镜治疗FAIS的既往吸烟者至少2年的患者报告结局(PROs),(2)将这些结果与倾向匹配的非吸烟对照组进行比较。
队列研究;证据等级为3级。
收集2008年12月至2017年11月期间接受初次髋关节镜治疗FAIS的所有患者的数据。如果患者表示既往吸烟但术前至少已戒烟1个月,且改良Harris髋关节评分(mHHS)、非关节炎髋关节评分(NAHS)及疼痛视觉模拟量表(VAS)有至少2年的术后结局,则符合纳入标准。记录达到最小临床重要差异(MCID)的髋关节百分比。然后根据年龄、性别和体重指数(BMI)将研究组与从不吸烟的患者按1:1的比例进行倾向匹配。
共纳入83例既往吸烟患者(84髋;年龄45.0±13.5岁),中位随访时间为38.6个月(四分位间距为27.5 - 48.2个月);所有患者术前平均±标准差14.3±24.5个月已戒烟。所有记录的PROs中,既往吸烟者从术前到至少2年随访均有显著改善(所有P均<0.001),并以良好的比例达到mHHS、NAHS和VAS的MCID(75.0% - 81.6%)。逻辑回归分析未发现戒烟时间与mHHS、NAHS或VAS达到MCID的比例之间存在显著关系。与84例从不吸烟者(84髋)相比,既往吸烟者术前评分、术后评分及所有记录的PROs改善情况相似(所有P>0.05)。两组达到mHHS、NAHS和VAS的MCID的比例相似,翻修手术率也相似。
接受初次髋关节镜治疗FAIS的既往吸烟者在至少2年随访时PROs有显著改善。与倾向匹配的从不吸烟对照组相比,他们术后PROs及达到心理测量阈值的比例相似。